Ask
Search
My library

About
Statistics
Contact
Data Protection
Accessibility
Imprint
Changelog
Frontend: v1.31.3
Backend: v1.11.4

We use cookies to provide a better user experience.

Data Protection

Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children

Burger, D.M.
Bastiaans, D.E.
Colbers, A.
et al.

Publication date

January 2015

DOI

10.1097/QAD.0000000000000862

Publisher

Ovid Technologies (Wolters Kluwer Health)

ISSN

0269-9370

Language

English

Abstract

Contains fulltext : 152551.pdf (publisher's version ) (Open Access

Extracted data

Related items

PRACTICE OF USING VIRAL PROTEASE INHIBITORS IN CHILDREN WITH HIV INFECTION

V.B. Denisenko
E.N. Simovan'yan
E.V. Beketova

February 2010

Selection of the most effective and safest high-active antiretroviral therapies is a critical issue ...

Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children.

Bergshoeff, A.S.
Fraaij, P.L.
Verweij, C.
Rossum, A.M. van
Verweel, G.

January 2004

Contains fulltext : 57985.pdf (publisher's version ) (Closed access

Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.

LePrevost, M.
Green, H.
Flynn, J.
Head, S.
Clapson, M.
Lyall, H.
Novelli, V.
Farrelly, L.
Walker, A.S.
Burger, D.M.
Gibb, D.

January 2006

Contains fulltext : 50519.pdf (publisher's version ) (Closed access)BACKGROUND: Da...

Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice

Gondrie, I.P.E.
Bastiaans, D.E.T.
Fraaij, P.L.
Driessen, G.J.
Knaap, L.C. van der
Visser, E.G.
Jaarsveld, P.
Groot, R. de
Hartwig, N.G.
Burger, D.M.
Rossum, A.M. van

January 2017

Contains fulltext : 176929.pdf (publisher's version ) (Closed access)BACKGROUND: T...

Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.

Lee (Helen Dowling Instituut), M. van der
Verweel, G.
Groot, R. de
Burger, D.M.

January 2006

Contains fulltext : 50981.pdf (publisher's version ) (Closed access)INTRODUCTION: ...

Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.

Lee (Helen Dowling Instituut), M. van der
Verweel, G.
Groot, R. de
Burger, D.M.

January 2006

INTRODUCTION: Lopinavir is an HIV protease inhibitor that is co-formulated with ritonavir. The appro...

Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice

Gondrie, I.P.E.
Bastiaans, D.E.T.
Fraaij, P.L.
Driessen, G.J.
Knaap, L.C. van der
Visser, E.G.
Jaarsveld, P.
Groot, R. de
Hartwig, N.G.
Burger, D.M.
Rossum, A.M. van

January 2017

BACKGROUND: The use of lopinavir/ritonavir once-daily (LPV/r QD) has not been approved for children....

Once-Daily versus Twice-Daily Lopinavir/Ritonavir

Martin S. King
Eugene Sun

October 2016

The safety, pharmacokinetics, and antiviral activity of lopinavir, a human immunodeficiency virus (H...

Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands

Bastiaans, D.E.T.
Forcat, S.
Lyall, H.
Cressey, T.R.
Hansudewechakul, R.
Kanjanavanit, S.
Noguera-Julian, A.
Konigs, C.
Inshaw, J.R.
Chalermpantmetagul, S.
Saidi, Y.
Compagnucci, A.
Harper, L.M.
Giaquinto, C.
Colbers, A.P.
Burger, D.M.

January 2014

Contains fulltext : 136012.pdf (publisher's version ) (Closed access)BACKGROUND: L...

Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.

Bergshoeff, A.S.
Fraaij, P.L.
Ndagijimana, J.
Verweel, G.
Hartwig, N.G.
Niehues, T.
Groot, R. de
Burger, D.M.

January 2005

Contains fulltext : 48066.pdf (publisher's version ) (Closed access)BACKGROUND: Nu...

Pharmacokinetics and Virological Efficacy after Switch to Once-Daily Lopinavir-Ritonavir in Treatment-Experienced HIV-1-Infected Children

Frantz Foissac
Saïk Urien
Pierre Frange
Marie-laure Chaix

January 2011

Lopinavir-ritonavir (LPV/r) is a protease inhibitor that is used twice daily (BID) in the treatment ...

Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications.

Porte, C.J.L. la
Schippers, E.F.
Ende, M.E. van der
Koopmans †, P.P.
Blok, W.L.
Kauffmann, R.H.
Kroon, F.P.
Burger, D.M.

January 2005

Contains fulltext : 49125.pdf (publisher's version ) (Closed access)We studied the...

Safety and efficacy of a NRTI sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1 infected children.

Fraaij, P.L.
Neubert, J.
Bergshoeff, A.S.
Rossum, A.M. van
Hartwig, N.G.
Schroten, H.
Korn, K.
Burger, D.M.
Groot, R. de
Niehues, T.

January 2004

Contains fulltext : 59320.pdf (publisher's version ) (Closed access

Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.

Fraaij, P.L.
Neubert, J.
Bergshoeff, A.S.
Rossum, A.M. van
Hartwig, N.G.
Schroten, H.
Korn, K.
Burger, D.M.
Groot, R. de
Niehues, T.

January 2004

Contains fulltext : 59321.pdf (publisher's version ) (Closed access)We studied a n...

PRACTICE OF USING VIRAL PROTEASE INHIBITORS IN CHILDREN WITH HIV INFECTION

V.B. Denisenko
E.N. Simovan'yan
E.V. Beketova

February 2010

Selection of the most effective and safest high-active antiretroviral therapies is a critical issue ...

PRACTICE OF USING VIRAL PROTEASE INHIBITORS IN CHILDREN WITH HIV INFECTION

V.B. Denisenko
E.N. Simovan'yan
E.V. Beketova

February 2010

Selection of the most effective and safest high-active antiretroviral therapies is a critical issue ...

Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children.

Bergshoeff, A.S.
Fraaij, P.L.
Verweij, C.
Rossum, A.M. van
Verweel, G.

January 2004

Contains fulltext : 57985.pdf (publisher's version ) (Closed access

Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.

LePrevost, M.
Green, H.
Flynn, J.
Head, S.
Clapson, M.
Lyall, H.
Novelli, V.
Farrelly, L.
Walker, A.S.
Burger, D.M.
Gibb, D.

January 2006

Contains fulltext : 50519.pdf (publisher's version ) (Closed access)BACKGROUND: Da...

Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice

Gondrie, I.P.E.
Bastiaans, D.E.T.
Fraaij, P.L.
Driessen, G.J.
Knaap, L.C. van der
Visser, E.G.
Jaarsveld, P.
Groot, R. de
Hartwig, N.G.
Burger, D.M.
Rossum, A.M. van

January 2017

Contains fulltext : 176929.pdf (publisher's version ) (Closed access)BACKGROUND: T...

Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.

Lee (Helen Dowling Instituut), M. van der
Verweel, G.
Groot, R. de
Burger, D.M.

January 2006

Contains fulltext : 50981.pdf (publisher's version ) (Closed access)INTRODUCTION: ...

Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.

Lee (Helen Dowling Instituut), M. van der
Verweel, G.
Groot, R. de
Burger, D.M.

January 2006

INTRODUCTION: Lopinavir is an HIV protease inhibitor that is co-formulated with ritonavir. The appro...

Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice

Gondrie, I.P.E.
Bastiaans, D.E.T.
Fraaij, P.L.
Driessen, G.J.
Knaap, L.C. van der
Visser, E.G.
Jaarsveld, P.
Groot, R. de
Hartwig, N.G.
Burger, D.M.
Rossum, A.M. van

January 2017

BACKGROUND: The use of lopinavir/ritonavir once-daily (LPV/r QD) has not been approved for children....

Once-Daily versus Twice-Daily Lopinavir/Ritonavir

Martin S. King
Eugene Sun

October 2016

The safety, pharmacokinetics, and antiviral activity of lopinavir, a human immunodeficiency virus (H...

Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands

Bastiaans, D.E.T.
Forcat, S.
Lyall, H.
Cressey, T.R.
Hansudewechakul, R.
Kanjanavanit, S.
Noguera-Julian, A.
Konigs, C.
Inshaw, J.R.
Chalermpantmetagul, S.
Saidi, Y.
Compagnucci, A.
Harper, L.M.
Giaquinto, C.
Colbers, A.P.
Burger, D.M.

January 2014

Contains fulltext : 136012.pdf (publisher's version ) (Closed access)BACKGROUND: L...

Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.

Bergshoeff, A.S.
Fraaij, P.L.
Ndagijimana, J.
Verweel, G.
Hartwig, N.G.
Niehues, T.
Groot, R. de
Burger, D.M.

January 2005

Contains fulltext : 48066.pdf (publisher's version ) (Closed access)BACKGROUND: Nu...

Pharmacokinetics and Virological Efficacy after Switch to Once-Daily Lopinavir-Ritonavir in Treatment-Experienced HIV-1-Infected Children

Frantz Foissac
Saïk Urien
Pierre Frange
Marie-laure Chaix

January 2011

Lopinavir-ritonavir (LPV/r) is a protease inhibitor that is used twice daily (BID) in the treatment ...

Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications.

Porte, C.J.L. la
Schippers, E.F.
Ende, M.E. van der
Koopmans †, P.P.
Blok, W.L.
Kauffmann, R.H.
Kroon, F.P.
Burger, D.M.

January 2005

Contains fulltext : 49125.pdf (publisher's version ) (Closed access)We studied the...

Safety and efficacy of a NRTI sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1 infected children.

Fraaij, P.L.
Neubert, J.
Bergshoeff, A.S.
Rossum, A.M. van
Hartwig, N.G.
Schroten, H.
Korn, K.
Burger, D.M.
Groot, R. de
Niehues, T.

January 2004

Contains fulltext : 59320.pdf (publisher's version ) (Closed access

Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.

Fraaij, P.L.
Neubert, J.
Bergshoeff, A.S.
Rossum, A.M. van
Hartwig, N.G.
Schroten, H.
Korn, K.
Burger, D.M.
Groot, R. de
Niehues, T.

January 2004

Contains fulltext : 59321.pdf (publisher's version ) (Closed access)We studied a n...

PRACTICE OF USING VIRAL PROTEASE INHIBITORS IN CHILDREN WITH HIV INFECTION

V.B. Denisenko
E.N. Simovan'yan
E.V. Beketova

February 2010

Selection of the most effective and safest high-active antiretroviral therapies is a critical issue ...

PRACTICE OF USING VIRAL PROTEASE INHIBITORS IN CHILDREN WITH HIV INFECTION

V.B. Denisenko
E.N. Simovan'yan
E.V. Beketova

February 2010

Selection of the most effective and safest high-active antiretroviral therapies is a critical issue ...

Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children.

Bergshoeff, A.S.
Fraaij, P.L.
Verweij, C.
Rossum, A.M. van
Verweel, G.

January 2004

Contains fulltext : 57985.pdf (publisher's version ) (Closed access

Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.

LePrevost, M.
Green, H.
Flynn, J.
Head, S.
Clapson, M.
Lyall, H.
Novelli, V.
Farrelly, L.
Walker, A.S.
Burger, D.M.
Gibb, D.

January 2006

Contains fulltext : 50519.pdf (publisher's version ) (Closed access)BACKGROUND: Da...